<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Drugs &#8211; Generic</title>
	<atom:link href="http://www.stockbloghub.com/category/drugs-generic/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MYL) Mylan Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/30/myl-mylan-incorporated-bull-of-the-day/91048</link>
		<comments>http://www.stockbloghub.com/2012/01/30/myl-mylan-incorporated-bull-of-the-day/91048#comments</comments>
		<pubDate>Mon, 30 Jan 2012 17:11:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91048</guid>
		<description><![CDATA[Mylan, Inc. (MYL) is one of the leading players in the US generics market. The company holds immense potential as many blockbuster drugs have begun to go off-patent and many more will lose patent exclusivity in the next few years. Moreover, we are encouraged by Mylan&#8217;s geographic reach and product depth along with a robust generic product pipeline. We believe the generic segment will post strong sales in 2012 benefiting from a slew of product launches already lined up. We have therefore upgraded our rating on Mylan from Neutral to Outperform to reflect our overall bullish stance for generic makers. Our target price for the stock is $26.00. MYLAN INC (MYL): Free Stock Analysis Report]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/30/myl-mylan-incorporated-bull-of-the-day/91048/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval</title>
		<link>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071</link>
		<comments>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071#comments</comments>
		<pubDate>Tue, 06 Dec 2011 00:54:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88071</guid>
		<description><![CDATA[Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food &#38; Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and Abbott Labs&#8216; (ABT) Norvir for the treatment of HIV/AIDS. The fixed drug combination has been pre-qualified to be used in treatment of experienced patients by the World Health Organization (WHO). It can also be used in combination with other antiretroviral (ARV) agents and will be eligible for purchase in certain developing countries. The drug was approved through the President&#8217;s Emergency Plan for AIDS Relief (PEPFAR). The drug will boost Mylan’s already strong portfolio of ARV’s in India. In a separate development, Mylan announced that Warner Chilcott Company (WCRX) filed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Approved for Zinecard Generic</title>
		<link>http://www.stockbloghub.com/2011/12/01/myl-mylan-approved-for-zinecard-generic/87803</link>
		<comments>http://www.stockbloghub.com/2011/12/01/myl-mylan-approved-for-zinecard-generic/87803#comments</comments>
		<pubDate>Thu, 01 Dec 2011 14:57:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87803</guid>
		<description><![CDATA[Mylan, Inc.’s (MYL) generic business was boosted further with the approval from the U.S. Food and Drug Administration (FDA) for its generic version of Pharmacia &#38; Upjohn&#8217;s Zinecard injection. Zinecard injection, which is a chemoprotective agent, recorded revenue of approximately $3.4 million for the trailing twelve months ending in September 2011. As of November 28, 2011, the company had 161 abbreviated new drug applications (ANDAs) that were pending clearance by the FDA, targeting $97.7 billion in branded sales. Mylan believes that about 43 of these ANDAs are first-to-file opportunities, representing more than $26.9 billion in branded sales. Earlier this month Mylan reached a settlement agreement with Novartis (NVS) relating to the generic version of the latter’s bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/01/myl-mylan-approved-for-zinecard-generic/87803/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles with Novartis</title>
		<link>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474</link>
		<comments>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:41:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87474</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic version of Vivelle-Dot on December 16, 2013, or earlier under certain circumstances. Mylan was the first to file an abbreviated new drug application (ANDA) with the US Food &#38; Drug Administration (FDA) to market the generic version of the drug. Accordingly, Mylan will enjoy an exclusivity period of 180 days when it will be the sole company to market the generic. The deal is subject to review by the US Department of Justice and the Federal Trade Commission. Earlier this month, Mylan entered into an agreement with Pfizer, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/31/wpi-watson-pharmaceuticals-bull-of-the-day-2/86174</link>
		<comments>http://www.stockbloghub.com/2011/10/31/wpi-watson-pharmaceuticals-bull-of-the-day-2/86174#comments</comments>
		<pubDate>Mon, 31 Oct 2011 15:46:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86174</guid>
		<description><![CDATA[Watson Pharmaceuticals, Inc. (WPI) posted second-quarter 2011 earnings of $1.01 per share, beating the Zacks Consensus Estimate by a penny and the year-ago earnings by $0.18 per share. Earnings were boosted by strong revenues, which jumped 24% to $1.08 billion, mainly driven by higher generic and branded sales. Following the better-than-expected results, Watson Pharmaceuticals increased its 2011 earning guidance range to $4.25-$4.50 per share from $3.95-$4.20. We have raised our 2011 earnings estimate to $4.46 per share. Moreover, we believe the company&#8217;s cost saving initiative and new product launches, both branded and generic, will help drive growth. We are upgrading Watson to Outperform. WATSON PHARMA (WPI): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/31/wpi-watson-pharmaceuticals-bull-of-the-day-2/86174/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles with Roche for Xeloda</title>
		<link>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911</link>
		<comments>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911#comments</comments>
		<pubDate>Fri, 23 Sep 2011 19:05:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83911</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that it has entered into a settlement and license agreement with Roche (RHHBY) bringing an end to its ongoing litigation with the latter relating to Roche’s cancer drug Xeloda. Mylan was looking to launch a generic version of the drug which is used for the treatment of metastatic breast and colorectal cancers. Xeloda generated revenue of $570 million in the trailing twelve months ending June 30, 2011, according to IMS Health. The details of the agreement have been kept confidential. The agreement will be applicable once it is reviewed by the US Department of Justice and the Federal Trade Commission. Mylan also recently announced that its Indian subsidiary, Matrix, has received tentative approval from the US Food and Drug Administration (FDA) to market a novel ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/myl-mylan-settles-with-roche-for-xeloda/83911/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Outperform on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145</link>
		<comments>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145#comments</comments>
		<pubDate>Fri, 26 Aug 2011 22:26:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82145</guid>
		<description><![CDATA[We continue to have an Outperform recommendation on Watson Pharmaceuticals, Inc. (WPI), with a target price of $79.00, following the release of second quarter 2011 results. Watson Pharma’s second quarter earnings of $1.01 per share (excluding special items) outpaced the Zacks Consensus Estimate by a penny and the year-ago earnings by 18 cents. Earnings were bolstered by higher revenues. Revenues for the quarter climbed 24% to $1.08 billion, beating the Zacks Consensus Estimate of $992 million. Revenues went up mainly due to increased generic and branded drug sales. Following the better-than-expected second quarter results, Watson Pharma increased its 2011 earning guidance range to $4.25-$4.50 per share from $3.95-$4.20. We note that the company enjoys a strong position in the generic pharmaceutical market. At the end of 2010, Watson Pharma had ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/26/wpi-watson-pharmaceuticals-analyst-maintains-outperform-on-shares/82145/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823</link>
		<comments>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823#comments</comments>
		<pubDate>Thu, 25 Aug 2011 16:48:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81823</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $19.00 following an appraisal of second quarter 2011 financial results. Mylan’s second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents and also beat the year-ago earnings 37 cents. Earnings growth was driven by an increase in generics revenue and improved gross margins. Mylan reports revenues from two segments: Generics and Specialty. Generic revenues grew 17% to $1.44 billion in the second quarter of 2011 as a decline in the Europe, Middle East &#38; Africa (EMEA) market was offset by growth in other markets like Asia-Pacific and North America. Mylan is one of the leading players in the generics market. A large number of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/25/myl-mylan-analyst-reaffirms-shares-at-neutral/81823/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle</title>
		<link>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630</link>
		<comments>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630#comments</comments>
		<pubDate>Thu, 18 Aug 2011 22:40:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81630</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine drug Frova. Mylan believes it is the first company to file an ANDA for generic Frova and is expecting to be granted 180 days of marketing exclusivity once approved. Frova generated revenues of approximately $68.2 million in the trailing twelve months ending on June 30, 2011. This month, Mylan launched the generic version of Uroxatral tablets. Some important products launched by Mylan in the recent past include generic versions of AstraZeneca&#8216;s (AZN) Entocort, Novartis&#8216; (NVS) Femara and Cephalon&#8216;s (CEPH) Amrix. Mylan has a robust generic pipeline. As of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Beats Second Quarter Earnings on All Fronts</title>
		<link>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033</link>
		<comments>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:22:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80033</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved gross margins. Quarter in Details Total revenues at Mylan climbed 15% over the prior year to $1.57 billion driven by increased sales of generic drugs and the positive impact of foreign exchange (Fx). Revenues were also ahead of the Zacks Consensus Estimate of $1.50 billion. Total revenues comprise both net revenues and other revenues from third parties. Mylan reports revenues through two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, Europe, Middle East &#38; Africa (EMEA), and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/07/14/wpi-watson-pharmaceuticals-bull-of-the-day/79050</link>
		<comments>http://www.stockbloghub.com/2011/07/14/wpi-watson-pharmaceuticals-bull-of-the-day/79050#comments</comments>
		<pubDate>Thu, 14 Jul 2011 18:47:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79050</guid>
		<description><![CDATA[Based on its first quarter performance and increased guidance, we are upgrading Watson Pharmaceuticals (WPI) to Outperform. The company posted first-quarter 2011 earnings of $0.89 per share, beating the Zacks Consensus Estimate by $0.03 and the year-ago earnings by $0.08 per share. Revenues increased 2% to $876.5 million, mainly driven by higher generics sales. Watson Pharma increased its 2011 earning guidance range to $3.95 &#8211; $4.20 per share from $3.85 &#8211; $4.15 per share. Following the earnings announcement, we raised our 2011 earnings estimate by 14 cents to $4.29 per share. We believe that the company&#8217;s cost saving initiatives and new product launches, both branded and generic, will help drive growth. Our target price of $82 is based on 19.1x our 2011 EPS estimate. WATSON PHARMA (WPI): Free Stock Analysis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/wpi-watson-pharmaceuticals-bull-of-the-day/79050/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Gets HIV Rights from Gilead</title>
		<link>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031</link>
		<comments>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:42:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79031</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access to HIV therapies in developing nations. The therapies include elvitegravir, an integrase inhibitor; cobicistat, an antiretroviral (ARV) boosting agent; and the &#8220;Quad,&#8221; a once-daily combination pill of elvitegravir, cobicistat and Gilead’s another HIV combination medicine Truvada (Emtriva+Viread). The rights are an extension of the non-exclusive license granted to Matrix to produce and sell active pharmaceutical ingredients and finished products, including generic versions of Viread and Truvada in 95 developing countries including India. The license has now been expanded to include 16 additional countries, the three investigational medicines and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Entangled in Legal Dispute</title>
		<link>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658</link>
		<comments>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658#comments</comments>
		<pubDate>Fri, 08 Jul 2011 20:49:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78658</guid>
		<description><![CDATA[The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement case against Watson Pharma relating to Vyvanse. Vyvanse is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 to 17 years and adults. The lawsuit comes in response to the  abbreviated new drug application (ANDA) filed by Watson Pharma with the US Food and Drug Administration (FDA) to market a generic version of Vyvanse. We note that the marketing exclusivity for Vyvanse expires in February 2012, under the Hatch-Waxman Act. By filing a patent infringement lawsuit, Shire has ensured a 30-month stay by the FDA. Consequently, the ANDA cannot be cleared by the regulatory body before August 23, 2014 or until a court ruling, whichever ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Restructures Branded Business</title>
		<link>http://www.stockbloghub.com/2011/07/05/prx-par-pharmaceutical-restructures-branded-business/78319</link>
		<comments>http://www.stockbloghub.com/2011/07/05/prx-par-pharmaceutical-restructures-branded-business/78319#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:22:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78319</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) is in for a strategic assessment as it announced restructuring plans for its branded drugs segment, Strativa Pharmaceuticals. The company will reduce its workforce by about 100 people as a result of the restructuring, which is expected to drive the Strativa business to profitability. The workforce reduction will help Par Pharma focus on its products, Megace ES and Nascobal. Consequently, in the second quarter of 2011, Par Pharma will incur one-time non-cash charges along with severance costs. The restructuring initiative is expected to generate operating expense savings of $8-$12 million for the rest of 2011. The company believes this initiative will boost Strativa to profitability in the near term. We expect the restructuring program to benefit the company, which witnessed a 20.9% drop in revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/prx-par-pharmaceutical-restructures-branded-business/78319/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals  and Columbia Laboratories Drug&#8217;s NDA Accepted</title>
		<link>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-and-columbia-laboratories-drugs-nda-accepted/77887</link>
		<comments>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-and-columbia-laboratories-drugs-nda-accepted/77887#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:59:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBRX]]></category>
		<category><![CDATA[Columbia Laboratories Inc]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77887</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) along with Columbia Laboratories Inc. (CBRX) recently announced that the latter’s New Drug Application (NDA) for Prochieve (progesterone gel) has been accepted by the US Food and Drug Administration (FDA). The companies are looking to get Prochieve approved for the reduction of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. However, Columbia Labs has withdrawn its request for priority review of the drug, following which the FDA has set a target date of February 26, 2012 for Prochieve. In July last year, Watson Pharma had acquired the US rights to Columbia Labs’ products Prochieve and Crinone. According to the purchase and collaboration agreement, following the FDA’s acceptance of the Prochieve NDA, Watson Pharma will have to make a $5 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-and-columbia-laboratories-drugs-nda-accepted/77887/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Files More Abbreviated New Drug Applications</title>
		<link>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565</link>
		<comments>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:11:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77565</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed Abbreviated New Drug Applications (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of GlaxoSmithKline plc’s (GSK) Avodart, indicated for the treatment of benign prostatic hyperplasia (BPH), and Novartis AG’s (NVS) Pataday 0.2%, indicated for the treatment of ocular itching that is associated with allergic conjunctivitis. In response, Glaxo filed a lawsuit against Watson Pharma in the United States District Court for the District of Delaware, and Alcon filed a lawsuit against Watson Pharma in the United States District Court for the Southern District of Indiana. Since both companies filed a suit within 30 days of the ANDA filing, the FDA cannot approve Watson Pharma’s generic Avodart and generic Pataday until November 17, 2013 and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Trial Date for Teva Pharmaceuticals / Mylan Dispute</title>
		<link>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026</link>
		<comments>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026#comments</comments>
		<pubDate>Wed, 22 Jun 2011 14:58:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Canadian Pacific Railway Limited]]></category>
		<category><![CDATA[CP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77026</guid>
		<description><![CDATA[Mylan Inc. (MYL) received some good news recently when a US District court denied Teva Pharmaceuticals Industries’ (TEVA) motion for a summary judgment, finding no inequitable conduct in the Copaxone infringement lawsuit. The court has ordered that the trial for inequitable conduct defense will commence on July 11, 2011. The remaining issues will be tried from September 7, 2011. Teva is challenging Mylan’s application for making a generic version of Teva&#8217;s Copaxone, a top selling drug for the treatment of multiple sclerosis. Copaxone loses patent protection in 2014. In December 2010 Teva filed a Citizen Petition (CP) with the FDA asking the agency to refuse approval to generic versions of Copaxone. The company said that any generic version of Copaxone should be subject to pre-clinical studies as well as full-scale ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/myl-trial-date-for-teva-pharmaceuticals-mylan-dispute/77026/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Wins Favorable Ruling Against Teva Pharmaceutical Industries</title>
		<link>http://www.stockbloghub.com/2011/06/21/wpi-watson-pharmaceuticals-wins-favorable-ruling-against-teva-pharmaceutical-industries/76922</link>
		<comments>http://www.stockbloghub.com/2011/06/21/wpi-watson-pharmaceuticals-wins-favorable-ruling-against-teva-pharmaceutical-industries/76922#comments</comments>
		<pubDate>Tue, 21 Jun 2011 17:11:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76922</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) recently announced that the United States District Court for the District of Nevada denied Teva Pharmaceutical Industries Ltd.’s (TEVA) request for a preliminary injunction and a temporary restraining order to prevent Watson Pharma from launching a generic version of Teva’s birth control drug, Seasonique. Earlier, in March, the US Court of Appeals for the Federal Circuit had ruled in favor of Watson Pharma in a case pertaining to a patent infringement suit involving Seasonique. The Appeals Court reversed and remanded a March 2010 ruling of the United States District Court for the District of Nevada, saying that Teva’s ‘969 patent is invalid and unenforceable, and Watson Pharma’s generic drug does not infringe the patent. Watson Pharma had filed an Abbreviated New Drug Application (ANDA) with the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/wpi-watson-pharmaceuticals-wins-favorable-ruling-against-teva-pharmaceutical-industries/76922/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Seeks Generic Viagra Approval</title>
		<link>http://www.stockbloghub.com/2011/06/16/wpi-watson-pharmaceuticals-seeks-generic-viagra-approval/75582</link>
		<comments>http://www.stockbloghub.com/2011/06/16/wpi-watson-pharmaceuticals-seeks-generic-viagra-approval/75582#comments</comments>
		<pubDate>Thu, 16 Jun 2011 15:09:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75582</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of Pfizer Inc.’s (PFE) erectile dysfunction (ED) drug, Viagra sildenafil citrate tablets. In response, Pfizer has filed a lawsuit against Watson Pharma in the United States District Court for the Southern District of New York. Since Pfizer filed a suit within 30 days of the ANDA filing, the FDA cannot approve Watson Pharma’s generic Viagra until November 6, 2013 or until the court ruling, whichever is earlier. Watson Pharma is seeking approval for the 25 mg, 50 mg and 100 mg dosage formulations of sildenafil citrate tablets. Viagra sales amounted to $1.9 billion in 2010. Last month, Watson Pharma launched the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/16/wpi-watson-pharmaceuticals-seeks-generic-viagra-approval/75582/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches New Generic Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053</link>
		<comments>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053#comments</comments>
		<pubDate>Fri, 27 May 2011 13:40:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=75053</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) generic portfolio continued to be boosted with the launch of the generic version of Xanodyne Pharmaceutical’s pain reliever Roxicodone. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The product recorded sales of $325 million in US for the twelve months endied March 31, 2011 according to data released by IMS Health. We note that the launch of the generic version of the pain reliever is the latest in the series of generic launches at Mylan. A couple of days ago the company, which is one of the largest generic and specialty pharmaceutical companies across the globe, launched its generic version of Abbott Laboratories’ (ABT) Depakote Sprinkle Capsules for treating seizures. The product recorded sales of $89 million in US for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/27/myl-mylan-launches-new-generic-pharmaceuticals/75053/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Launches Generic Drugs</title>
		<link>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321</link>
		<comments>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321#comments</comments>
		<pubDate>Sat, 21 May 2011 13:54:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74321</guid>
		<description><![CDATA[MylanInc. (MYL) recently launched its generic version of Ista Pharmaceuticals Inc’s (ISTA) Xibrom ophthalmic solution, used for the treatment of inflammation in patients who have undergone a cataract extraction operation. The generic has been launched under a development and supply agreement with Coastal Pharmaceuticals. The branded product recorded sales of $116 million in US for the twelve months ending on March 31, 2011. Mylan also recently announced launches of generic versions of Cephalon’s (CEPH) Amrix which is a muscle relaxant and Johnson &#38; Johnson’s (JNJ) Risperdal which is used for the treatment of schizophrenia. As of May 16, 2011, the company had 169 abbreviated new drug applications (ANDAs) pending US Food and Drug Administration (FDA) approval targeting $100.7 billion in branded sales. Mylan believes that about 45 of the pending ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/21/myl-mylan-launches-generic-drugs/74321/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Beats on Earnings &#8211; Increases Guidance</title>
		<link>http://www.stockbloghub.com/2011/05/03/wpi-watson-pharmaceuticals-beats-on-earnings-increases-guidance/72592</link>
		<comments>http://www.stockbloghub.com/2011/05/03/wpi-watson-pharmaceuticals-beats-on-earnings-increases-guidance/72592#comments</comments>
		<pubDate>Tue, 03 May 2011 19:37:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBRX]]></category>
		<category><![CDATA[Columbia Laboratories Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72592</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc.&#8216;s  (WPI) first quarter 2011 earnings (excluding special items) of 89 cents per share beat the Zacks Consensus Estimate by 3 cents and the year-ago earnings by 8 cents. Earnings were bolstered by higher revenues and reduced cost, resulting from a lower number of third-party product launches in the Distribution segment. Quarterly Details Revenues increased 2% to $876.5 million, mainly due to increased generic sales during the quarter. First quarter revenues however missed the Zacks Consensus Estimate of $906 million. Watson Pharma&#8217;s Global Generics segment posted sales of $600.1 million, up 10%. The upside was driven by increased sales of extended-release products and the launch of new products such as Zarah (generic version of Bayer AG’s (BAYRY) Yasmin). International product sales for the division in the reported quarter came ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/wpi-watson-pharmaceuticals-beats-on-earnings-increases-guidance/72592/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Meets Analyst Estimates &#8211; Sales Upbeat</title>
		<link>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045</link>
		<comments>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045#comments</comments>
		<pubDate>Tue, 03 May 2011 18:03:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73045</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) first quarter 2011 earnings (excluding special items) of 44 cents per share were in line with the Zacks Consensus Estimate. A higher quarterly tax rate, increased share count and pricing pressure in Europe offset the increase in generics revenue in North America to deliver in line earnings growth. Earnings were nevertheless 22% above year-ago earnings of 36 cents per share. Quarter in Details Total revenues at Mylan climbed 12.1% over the prior year to $1.45 billion driven by increased sales of generic drugs. Revenue was also barely above the Zacks Consensus Estimate of $1.44 billion. Total revenues comprises both net revenues and other revenues from third parties. Mylan reports revenues from two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/20/myl-mylan-analyst-maintains-neutral-rating-on-shares/69247</link>
		<comments>http://www.stockbloghub.com/2011/03/20/myl-mylan-analyst-maintains-neutral-rating-on-shares/69247#comments</comments>
		<pubDate>Mon, 21 Mar 2011 03:26:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=69247</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Mylan Inc. (MYL) with a target price of $23.00 after appraising fourth quarter and fiscal year 2010 financial results. Mylan’s fourth quarter 2010 earnings (excluding special items) of 45 cents per share were at par with the Zacks Consensus Estimate. Higher operating expenses offset the increase in revenue to deliver in line earnings growth. Earnings were however well above the year-ago figure of 33 cents per share. Revenues climbed 6% to $1.43 billion but fell short of the Zacks Consensus Estimate of $1.46 billion. Mylan reports revenues from two segments: Generics and Specialty. Generic revenues grew 5.5% to $1.35 billion in the final quarter of 2010 as a decline in the Europe, Middle East &#38; Africa (EMEA) market was offset by growth in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/20/myl-mylan-analyst-maintains-neutral-rating-on-shares/69247/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917</link>
		<comments>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917#comments</comments>
		<pubDate>Thu, 17 Mar 2011 17:02:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABC]]></category>
		<category><![CDATA[AmerisourceBergen Corporation]]></category>
		<category><![CDATA[CAH]]></category>
		<category><![CDATA[Cardinal Health Inc.]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68917</guid>
		<description><![CDATA[We recently reaffirmed our Neutral stance on Watson Pharmaceuticals Inc. (WPI) following the release of fourth quarter and fiscal year 2010 financial results. Quarterly earnings of 93 cents per share were in line with the Zacks Consensus Estimate and 8 cents above the year-ago earnings. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. For full year 2010, Watson Pharma earned $3.42 per share (up 12.5%) on revenues of $3.6 billion (up 28%). The Zacks Consensus Estimate for 2010 was $3.42 per share on revenues of $3.5 billion. We believe that the company’s cost saving initiative and new product launches, both branded and generic, will help drive growth. We have raised our ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/wpi-watson-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/68917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Quarterly Earnings Report Outperforms Expectations</title>
		<link>http://www.stockbloghub.com/2011/02/16/wpi-watson-pharmaceuticals-quarterly-earnings-report-outperforms-expectations/67018</link>
		<comments>http://www.stockbloghub.com/2011/02/16/wpi-watson-pharmaceuticals-quarterly-earnings-report-outperforms-expectations/67018#comments</comments>
		<pubDate>Wed, 16 Feb 2011 18:12:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67018</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc.&#8216;s  (WPI) fourth quarter 2010 earnings (excluding special items) of $0.93 per share were in line with the Zacks Consensus Estimate and $0.08 above the year-ago earnings. Earnings, however, dropped 70.6% to $0.15 per share on a reported basis (including special items) because of legal charges. Revenues increased 21.2% to $952.7 million, mainly due to the strong performance of the generics business. Fourth quarter revenues surpassed the Zacks Consensus Estimate of $921 million. Performance by Segment for the Quarter Watson Pharma&#8217;s Global Generics segment posted sales of $646 million, up 38.2%. The increase in sales was driven by contribution from new international markets, the launch of new products such as metoprolol succinate extended-release, Zarah (generic version of Bayer’s (BAYRY) Yasmin) and diltiazem extended-release. International product sales for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/16/wpi-watson-pharmaceuticals-quarterly-earnings-report-outperforms-expectations/67018/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval for Generic Version of Valtrex</title>
		<link>http://www.stockbloghub.com/2010/05/30/myl-mylan-earns-fda-approval-for-generic-version-of-valtrex/38900</link>
		<comments>http://www.stockbloghub.com/2010/05/30/myl-mylan-earns-fda-approval-for-generic-version-of-valtrex/38900#comments</comments>
		<pubDate>Sun, 30 May 2010 17:11:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=38900</guid>
		<description><![CDATA[Recently, Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for its generic version of GlaxoSmithKline’s (GSK) Valtrex, a treatment for herpes virus infection. The drug recorded US sales of about $2.15 billion in 2009 for the twelve months ending March 2010. Apart from Mylan, Teva Pharmaceuticals (TEVA), Watson Pharma (WPI) and Sandoz, the generic arm of Novartis (NVS) have also received approval. Following the approval of Valtrex, Mylan’s generic portfolio will become stronger. In the past few months, Mylan has received many significant approvals. These include the generic versions of Glaxo’s smoking cessation aid, Zyban; Boehringer Ingelheim&#8217;s benign prostatic hyperplasia (BPH) treatment, Flomax and Lundbeck’s Desoxyn. Mylan received a significant approval in the field of HIV treatment for its subsidiary, Matrix. The company has received ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/30/myl-mylan-earns-fda-approval-for-generic-version-of-valtrex/38900/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan First Quarter 2010 Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2010/05/24/myl-mylan-first-quarter-2010-earnings-scorecard/37661</link>
		<comments>http://www.stockbloghub.com/2010/05/24/myl-mylan-first-quarter-2010-earnings-scorecard/37661#comments</comments>
		<pubDate>Mon, 24 May 2010 21:27:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37661</guid>
		<description><![CDATA[First Quarter Highlights On April 29, Mylan (MYL) reported first quarter fiscal 2010 earnings per share (EPS) of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted basis, first quarter earnings came in at 36 cents, a couple of cents above the Zacks Consensus Estimate and well above the year-ago earnings of 33 cents. Revenues increased 7% to $1.29 billion, mainly due to a positive foreign exchange (FX) impact. Excluding the favorable FX impact, revenues would have increased 2%. Mylan reiterated its guidance for 2010. The EPS is expected in the range of $1.50 to $1.70 and the company expects to generate total revenues of $5.45 to $5.75 billion. Agreement of Analysts Following the release of first quarter results, estimate revision trends among the analysts depict ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/myl-mylan-first-quarter-2010-earnings-scorecard/37661/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Demonstrates Growth in Generic Drugs</title>
		<link>http://www.stockbloghub.com/2010/05/20/wpi-watson-pharmaceuticals-demonstrates-growth-in-generic-drugs/37800</link>
		<comments>http://www.stockbloghub.com/2010/05/20/wpi-watson-pharmaceuticals-demonstrates-growth-in-generic-drugs/37800#comments</comments>
		<pubDate>Thu, 20 May 2010 20:30:44 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37800</guid>
		<description><![CDATA[Financial Tides likes Watson Pharmaceuticals, Inc. (WPI) a pharmaceutical company primarily engaged in the development, production, marketing and distribution of both branded and off-patent pharmaceutical products. The company&#8217;s branded pharmaceutical business operates primarily in three specialty areas: Dermatology, Women&#8217;s Health and General Products. The company&#8217;s products include therapeutic and preventive agents generally sold by prescription or over-the-counter for the treatment of human diseases and disorders. The big story is in the acquisition of the Arrow Group. Although the acquisition required the issuance of 17 million shares that dilutes earning per share, overall sales should benefit because it will allow the company to enter new over seas markets. Growth will come in new offerings of generic drugs in the areas of urology, birth control and a new generic version of Lipitor ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/20/wpi-watson-pharmaceuticals-demonstrates-growth-in-generic-drugs/37800/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan&#8217;s Quarterly Earnings Tops Expectations</title>
		<link>http://www.stockbloghub.com/2010/04/29/myl-mylans-quarterly-earnings-tops-expectations/35671</link>
		<comments>http://www.stockbloghub.com/2010/04/29/myl-mylans-quarterly-earnings-tops-expectations/35671#comments</comments>
		<pubDate>Fri, 30 Apr 2010 00:15:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35671</guid>
		<description><![CDATA[Mylan (MYL) reported first quarter earnings per share of 20 cents, down from the year-ago earnings of 23 cents. On an adjusted basis, first quarter 2010 earnings came in at 36 cents, a couple of cents above the Zacks Consensus Estimate and well above the year-ago earnings of 33 cents. Revenues increased 7% to $1.29 billion, mainly due to a positive foreign exchange (FX) impact. Excluding the favorable FX impact, revenues would have increased 2% to $20.6 million. Both revenue segments at Mylan recorded growth during the first quarter. While Generics accounted for about 96% of total first quarter revenues, posting sales of $1.24 billion (up 7.8%), revenues from the Specialty segment increased 20.7% to $101 million. Specialty revenues were driven by higher sales of Dey&#8217;s EpiPen Auto-Injector, Perforomist Solution, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/myl-mylans-quarterly-earnings-tops-expectations/35671/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HITK) Hi-Tech Pharmacal &#8211; Reports Another Earnings Surprise</title>
		<link>http://www.stockbloghub.com/2010/04/12/hitk-hi-tech-pharmacal-reports-another-earnings-surprise/33401</link>
		<comments>http://www.stockbloghub.com/2010/04/12/hitk-hi-tech-pharmacal-reports-another-earnings-surprise/33401#comments</comments>
		<pubDate>Mon, 12 Apr 2010 17:26:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hi Tech Pharmacal Company Inc]]></category>
		<category><![CDATA[HITK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33401</guid>
		<description><![CDATA[Hi-Tech Pharmacal Co. (HITK) continues to trade at great valuations and have plenty of earnings momentum. Company Description Hi-Tech Pharmacal makes generic and branded pharmaceuticals, both over-the-counter and prescription. The company focuses on liquid and semi-solid forms for ophthalmic, otic, and inhalable products. Another Surprise Hi-Tech Pharmacal reported quarterly results on Mar 11 that yielded EPS of 67 cents, 17 cents ahead of the Zacks Consensus Estimate. This was the company&#8217;s fourth consecutive earnings surprise. Sales jumped 32% to $38.8 million during the period. Estimates Pop Following the earnings release full-year estimates for fiscal 2010 jumped to $2.44, up from $2.06 over the past 3 months. The revisions have kept shares of HITK cheap. The stock is trading at just 9 times forward earnings. Estimates for next year are expected ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/12/hitk-hi-tech-pharmacal-reports-another-earnings-surprise/33401/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Companies &#8211; Earnings Surprised in the Fourth Quarter by 14%</title>
		<link>http://www.stockbloghub.com/2010/04/09/prx-par-pharmaceutical-companies-earnings-surprised-in-the-fourth-quarter-by-14/33279</link>
		<comments>http://www.stockbloghub.com/2010/04/09/prx-par-pharmaceutical-companies-earnings-surprised-in-the-fourth-quarter-by-14/33279#comments</comments>
		<pubDate>Fri, 09 Apr 2010 21:39:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33279</guid>
		<description><![CDATA[Par Pharmaceutical Companies Inc. (PRX) has surprised on the Zacks Consensus Estimate 4 quarters in a row by an average of 47%. PRX is trading with a forward P/E of only 12.6. Company Description Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States. It has two divisions, Par Pharmaceutical, its generic drug segment, and Strativa Pharmaceuticals, its proprietary products segment which launched in 2005. It currently markets and/or licenses more than 85 prescription drug products and has more than 30 products in active development. Par Surprised in the Fourth Quarter by 14% On Feb 24, Par Pharmaceutical reported fourth quarter results which beat the Zacks consensus by 8 cents. Earnings per share ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/09/prx-par-pharmaceutical-companies-earnings-surprised-in-the-fourth-quarter-by-14/33279/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval For Laxative Candidate</title>
		<link>http://www.stockbloghub.com/2010/04/08/myl-mylan-earns-fda-approval-for-laxative-candidate/33214</link>
		<comments>http://www.stockbloghub.com/2010/04/08/myl-mylan-earns-fda-approval-for-laxative-candidate/33214#comments</comments>
		<pubDate>Thu, 08 Apr 2010 21:19:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33214</guid>
		<description><![CDATA[Mylan Inc. (MYL) received approval from the US Food and Drug Administration (FDA) for the generic version of Braintree Laboratories&#8217; NuLytely, a laxative. The company is eligible to ship the product immediately, which recorded US sales of about $31 million in 2009. Following this approval, Mylan’s generic portfolio will be strengthened further. We are also happy to note that in March 2010, the company had entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs &#8212; Actoplus Met and Actos &#8212; which recorded 2009 sales of $459 million and $3.4 billion, respectively. Mylan has received quite a few significant approvals in 2009 including the generic version of Bristol-Myers Squibb&#8217;s (BMY) Sinemet for treating Parkinson’s and Takeda Pharmaceuticals&#8217; proton pump inhibitor Prevacid delayed-release (DR) capsules. The company has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/08/myl-mylan-earns-fda-approval-for-laxative-candidate/33214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Strengthens Drug Portfolio</title>
		<link>http://www.stockbloghub.com/2010/03/17/myl-mylan-strengthens-drug-portfolio/30934</link>
		<comments>http://www.stockbloghub.com/2010/03/17/myl-mylan-strengthens-drug-portfolio/30934#comments</comments>
		<pubDate>Wed, 17 Mar 2010 22:27:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30934</guid>
		<description><![CDATA[Mylan Inc. (MYL) has entered into an agreement with Takeda Pharmaceutical for two type II diabetes drugs – Actoplus Met and Actos, which recorded 2009 sales of $459 million and $3.4 billion, respectively. Following the agreement, Mylan will be able to launch the generic versions of Actoplus Met on Dec 14, 2012 and Actos on Aug 17, 2012 or earlier under certain circumstances. The company expects to be eligible for 180 days of marketing exclusivity for both the drugs on approval. Mylan has received quite a few significant approvals in 2009 including for the generic version of Bristol-Myers Squibb&#8217;s (BMY) Sinemet for treating Parkinson’s and Takeda Pharmaceuticals&#8217; proton pump inhibitor Prevacid delayed-release (DR) capsules. The company also settled its dispute with Pfizer (PFE) related to antifungal drug Vfend (voriconazole), following ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/17/myl-mylan-strengthens-drug-portfolio/30934/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($MYL) Mylan Beats Earnings Expectations &#8211; Outlook Robust</title>
		<link>http://www.stockbloghub.com/2010/02/25/myl-mylan-beats-earnings-expectations-outlook-robust/29055</link>
		<comments>http://www.stockbloghub.com/2010/02/25/myl-mylan-beats-earnings-expectations-outlook-robust/29055#comments</comments>
		<pubDate>Thu, 25 Feb 2010 20:47:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29055</guid>
		<description><![CDATA[Mylan (MYL) reported fourth quarter earnings per share (EPS) of 33 cents, surpassing the Zacks Consensus Estimate of 30 cents and 26 cents in the prior-year period. For the full year 2009, EPS came in at $1.30, up 62.5% from 80 cents in 2008. Mylan reported revenues of $1.35 billion, a 12% increase compared to $1.20 billion in the year-ago period. Revenues were favorably impacted by the foreign currency translation. For the full year, the company recorded $5.09 billion in sales, marginally lower than $5.14 billion in the previous year, which included $468.1 million of previously deferred revenue related to its sale of Bystolic rights. From the third quarter of 2009, Mylan has decided to report its results in two segments &#8212; Generics and Specialty &#8212; following the acquisition of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/25/myl-mylan-beats-earnings-expectations-outlook-robust/29055/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Sees 16 Analysts Raising Fourth Quarter Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214</link>
		<comments>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214#comments</comments>
		<pubDate>Thu, 28 Jan 2010 01:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26214</guid>
		<description><![CDATA[Watson Pharmaceuticals, Inc. (WPI) reports fourth-quarter results on February 23, with the current Zacks Consensus Estimate at 72 cents per share. Estimates appear to be modestly up, with one of the 16 analysts covering the stock raising fourth quarter estimates in the last 30 days. In terms of earnings surprises, Watson had a modest positive surprise in the third quarter and a 7% positive surprise in the second quarter of 2009, with the four-quarter average of 8%. (This means, on average, Watson has come ahead of the Zacks Consensus by 8% over the last four quarters.) If quarterly results come in-line with expectations, fourth quarter 2009 EPS would be 35.8% above the year-ago level. However, chances are high that there could be a positive surprise of 1.4% for the upcoming ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/wpi-watson-pharmaceuticals-sees-16-analysts-raising-fourth-quarter-estimates/26214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Set to Top Expectations</title>
		<link>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019</link>
		<comments>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019#comments</comments>
		<pubDate>Thu, 14 Jan 2010 22:21:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25019</guid>
		<description><![CDATA[Watson Pharmaceuticals, Inc. (WPI) recently announced that it expects 2009 earnings to meet or exceed guidance provided by the company in Nov. 2009. The company had earlier guided towards earnings in the range of $2.50 &#8211; $2.58 per share. Watson also announced that it expects revenues to increase 9% year over year to $2.7 billion in 2009. The company’s shares reacted positively to the news, with the stock gaining roughly 3.5% since the announcement. The statement, which was made at the 28th Annual J.P. Morgan (JPM) Healthcare Conference, is based on a preliminary review of the company’s performance in the fourth quarter and year-ended December 31, 2009. Watson attributed the robust performance to strong contributions from its new generic and brand products, and significant growth in distribution revenues in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/14/wpi-watson-pharmaceuticals-set-to-top-expectations/25019/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593</link>
		<comments>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593#comments</comments>
		<pubDate>Sun, 10 Jan 2010 23:33:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24593</guid>
		<description><![CDATA[We recently initiated coverage on Watson Pharmaceuticals, Inc. (WPI) with a “Neutral&#8221; recommendation and a target price of $42. The company enjoys a strong position in the generics market. We believe the company’s strategy of developing generics that are difficult to formulate or manufacture will help strengthen its position in the market. Going forward Incorporatedreasing awareness about generics, initiatives taken by various government and private agencies encouraging the use of low-cost generics, an aging population and a corresponding increase in healthcare costs, as well as the large number of branded products losing patent protection over the coming years, should lead to continued expansion of the generics market. We also believe that Watson’s recent acquisition of Arrow will help the company expand its footprint in ex-U.S. territories, and will also boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/10/wpi-watson-pharmaceuticals-coverage-initiated-at-neutral/24593/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HITK) Hi-Tech Pharmacal Co. &#8211; Earnings Estimates Jump Big!</title>
		<link>http://www.stockbloghub.com/2009/12/29/hitk-hi-tech-pharmacal-co-earnings-estimates-jump-big/23802</link>
		<comments>http://www.stockbloghub.com/2009/12/29/hitk-hi-tech-pharmacal-co-earnings-estimates-jump-big/23802#comments</comments>
		<pubDate>Tue, 29 Dec 2009 19:17:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hi Tech Pharmacal Company Inc]]></category>
		<category><![CDATA[HITK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23802</guid>
		<description><![CDATA[Hi-Tech Pharmacal Co (HITK) estimates are surging following the latest earnings report, which showed earnings rise more than 600%. Company Description Hi-Tech makes generic and branded pharmaceuticals, both over-the-counter and prescription. The company focuses on liquid and semi-solid forms for ophthalmic, otic, and inhalable products. Quarterly Results On Dec 9 Hi-Tech reported second-quarter results that showed sales increased by 64%, to just under $41 million. This led to a surge in net income, which was up almost 7 fold, to $7.4 million. Earnings per share came in at 60 cents, 28 cents higher than the Zacks Consensus Estimate. This was the third consecutive earnings surprise. Estimates Jump Full-year estimates for fiscal 2010 are now averaging $2.06, up from $1.42 over the past 30 days. This is compared to 78 cents ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/29/hitk-hi-tech-pharmacal-co-earnings-estimates-jump-big/23802/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Inc Acquires Arrow Group</title>
		<link>http://www.stockbloghub.com/2009/12/09/wpi-watson-pharmaceuticals-inc-acquires-arrow-group/22383</link>
		<comments>http://www.stockbloghub.com/2009/12/09/wpi-watson-pharmaceuticals-inc-acquires-arrow-group/22383#comments</comments>
		<pubDate>Wed, 09 Dec 2009 23:23:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22383</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) recently completed its acquisition of privately held Arrow Group. The company closed its $1.75 billion cash and stock buyout of Arrow after receiving the green signal from the Federal Trade Commission (FTC). The terms of the deal, initially announced in June 2009 Incorporatedluded a cash payment of $1.05 billion, and the issuance of 16.9 million shares of Watson common stock. Moreover, $200 million in the form of zero-coupon, non-convertible preferred shares were placed in escrow for the benefit of the Arrow shareholders. These shares will be redeemable in 2012. Arrow shareholders will also receive additional contingent payments based on sales of the authorized generic version of Pfizer’s (PFE) Lipitor. Watson used cash on hand and borrowings of $275 million under its $500 million revolving credit facility ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/09/wpi-watson-pharmaceuticals-inc-acquires-arrow-group/22383/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Cos. &#8211; Revenue Doubles &#8211; Earnings Estimates Jump</title>
		<link>http://www.stockbloghub.com/2009/12/04/prx-par-pharmaceutical-cos-revenue-doubles-earnings-estimates-jump/22005</link>
		<comments>http://www.stockbloghub.com/2009/12/04/prx-par-pharmaceutical-cos-revenue-doubles-earnings-estimates-jump/22005#comments</comments>
		<pubDate>Sat, 05 Dec 2009 02:04:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22005</guid>
		<description><![CDATA[Par Pharmaceutical Cos. (PRX) continues to climb as analysts raise estimates on another earnings surprise. Company Description Par Pharmaceutical makes generic drugs and other branded pharmaceuticals. Currently, the company has 4 trademarked drugs and numerous generics. Revenue Doubles The company&#8217;s third-quarter results, released Nov 6, showed revenue of $295 million, up from $149 million last year. This lead to net income of $26.3 million, exponentially higher than the $0.5 million at the same time last year. Earnings per share came in at 77 cents, compared to just 1 penny last year. Analysts were looking for just 49 cents, making this the third consecutive earnings surprise. Estimates Jump The Zacks Consensus Estimate for full-year 2009 and 2010 both jumped on the news. Current year forecasts are averaging $2.46, up from $1.88. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/04/prx-par-pharmaceutical-cos-revenue-doubles-earnings-estimates-jump/22005/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Wins FDA Approval for Their Abbreviated New Drug Application</title>
		<link>http://www.stockbloghub.com/2009/11/14/myl-mylan-wins-fda-approval-for-their-abbreviated-new-drug-application/20490</link>
		<comments>http://www.stockbloghub.com/2009/11/14/myl-mylan-wins-fda-approval-for-their-abbreviated-new-drug-application/20490#comments</comments>
		<pubDate>Sat, 14 Nov 2009 22:37:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20490</guid>
		<description><![CDATA[Recently, Mylan Inc.‘s (MYL) subsidiary, Matrix Laboratories received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Lansoprazole Delayed-release (DR) capsules in two dosage forms (15 mg and 30 mg). Mylan plans to begin shipment of the product immediately. The drug is the generic version of Takeda Pharmaceuticals&#8217; (TKPHY.PK) proton pump inhibitor Prevacid DR Capsules. According to IMS Health (RX), the branded version had US sales of approximately $3 billion for the 12 months ending June 30. Mylan received quite a few approvals in the recent past. In October, Mylan settled its dispute with Pfizer (PFE) related to the patent of antifungal drug Vfend (voriconazole), following which Mylan received the approval to launch the generic version of the drug. Additionally, in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/14/myl-mylan-wins-fda-approval-for-their-abbreviated-new-drug-application/20490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Beats Expectations &#8211; Raises Outlook</title>
		<link>http://www.stockbloghub.com/2009/11/01/myl-mylan-beats-expectations-raises-outlook/19236</link>
		<comments>http://www.stockbloghub.com/2009/11/01/myl-mylan-beats-expectations-raises-outlook/19236#comments</comments>
		<pubDate>Sun, 01 Nov 2009 23:20:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19236</guid>
		<description><![CDATA[Mylan, Inc. (MYL) reported third quarter earnings per share of 32 cents, above both the Zacks Consensus Estimate of 27 cents and 23 cents in the prior-year period. The company reported revenues of $1.26 billion, a 24% decline from the year-ago period. However, the year-ago period included $455 million of revenue related to the sale of the product rights of Bystolic. Excluding this, total revenues increased 5.2% over the third quarter 2008. Revenues would have increased 9%, but for the unfavorable movement of foreign currency. From this quarter onwards, Mylan has decided to report its results in two segments &#8212; Generics and Specialty &#8212; following the acquisition of approximately 24% of the remaining interest in Matrix and the related de-listing. The former Matrix segment has been included in the Generics ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/01/myl-mylan-beats-expectations-raises-outlook/19236/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Companies, Inc. &#8211; Beat by 35.42% in the Second Quarter</title>
		<link>http://www.stockbloghub.com/2009/10/21/prx-par-pharmaceutical-companies-inc-beat-by-35-42-in-the-second-quarter/18350</link>
		<comments>http://www.stockbloghub.com/2009/10/21/prx-par-pharmaceutical-companies-inc-beat-by-35-42-in-the-second-quarter/18350#comments</comments>
		<pubDate>Wed, 21 Oct 2009 23:15:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18350</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) has surprised on the Zacks Consensus Estimate 3 out of the last 4 quarters by an average of 101.93%. With earnings estimates jumping, the company has a PEG ratio of just 0.2. Company Description Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States. The branded division, Strativa Pharmaceuticals, was launched in 2005 and has licensed 4 proprietary drugs that are in development. Third Quarter Zacks Consensus Estimate Rises As the third quarter earnings report scheduled for Nov 5 approaches, analysts are becoming more bullish on Par. In just the last week, 3 out of 8 covering analysts have raised estimates by 3 cents to 47 cents per ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/prx-par-pharmaceutical-companies-inc-beat-by-35-42-in-the-second-quarter/18350/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Par Pharmaceutical Companies &#8211; Beat by 35.42% in the Second Quarter</title>
		<link>http://www.stockbloghub.com/2009/10/20/prx-par-pharmaceutical-companies-beat-by-35-42-in-the-second-quarter/18169</link>
		<comments>http://www.stockbloghub.com/2009/10/20/prx-par-pharmaceutical-companies-beat-by-35-42-in-the-second-quarter/18169#comments</comments>
		<pubDate>Tue, 20 Oct 2009 20:33:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18169</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) has surprised on the Zacks Consensus Estimate 3 out of the last 4 quarters by an average of 101.93%. With earnings estimates jumping, the company has a PEG ratio of just 0.2. Company Description Par Pharmaceutical manufactures generic drugs and branded pharmaceuticals for the specialty markets. The company ranks among the top ten in generic drug sales in the United States. The branded division, Strativa Pharmaceuticals, was launched in 2005 and has licensed 4 proprietary drugs that are in development. Third Quarter Zacks Consensus Estimate Rises As the third quarter earnings report scheduled for Nov 5 approaches, analysts are becoming more bullish on Par. In just the last week, 3 out of 8 covering analysts have raised estimates by 3 cents to 47 cents per ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/20/prx-par-pharmaceutical-companies-beat-by-35-42-in-the-second-quarter/18169/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles Dispute with Pfizer</title>
		<link>http://www.stockbloghub.com/2009/10/16/myl-mylan-settles-dispute-with-pfizer/17812</link>
		<comments>http://www.stockbloghub.com/2009/10/16/myl-mylan-settles-dispute-with-pfizer/17812#comments</comments>
		<pubDate>Fri, 16 Oct 2009 23:40:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17812</guid>
		<description><![CDATA[Recently, Mylan (MYL) announced the settlement of its dispute with Pfizer (PFE) related to the patent of antifungal drug Vfend (voriconazole). Now Mylan can launch an authorized generic version of the drug in two dosage forms of 50 mg and 200 mg tablets in early 2011. Mylan’s subsidiary, Matrix Laboratories, has Food and Drug Administration (FDA) approval for the generic version of the drug. Being the first company to submit an Abbreviated New Drug Application (ANDA), Matrix expects to be eligible to receive 180 days of marketing exclusivity for the drug. However, the agreement does not include liquid or intravenous versions of Vfend. The agreement has yet to be approved by the US Department of Justice and the Federal Trade Commission. Vfend recorded sales of $164 million in the 12 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/myl-mylan-settles-dispute-with-pfizer/17812/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRX) Top Performer for Thurs: Par Pharmaceutical Companies</title>
		<link>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743</link>
		<comments>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743#comments</comments>
		<pubDate>Thu, 15 Oct 2009 22:29:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Hi Tech Pharmacal Company Inc]]></category>
		<category><![CDATA[HITK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17743</guid>
		<description><![CDATA[Par Pharmaceutical Companies, Inc. (PRX) received a brokerage firm upgrade today, which is helping it to gain during a rather muted morning session. In addition, PRX has been enjoying rising earnings estimates that have pushed the 2009 and 2010 Zacks Consensus Estimates higher in just the past 7 days. The company made the Zacks #1 Rank Top Performers List for Thursday with shares that are up approximately 4.4%. Volume is at 716,000 shares; above the daily average of 301,000. Par Pharmaceutical develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. It is part of the Medical-Generic Drugs industry. There are 3 other names from this space on today&#8217;s Zacks #1 Rank List: Dr. Reddy&#8217;s Laboratories Ltd. (RDY), Hi-Tech Pharmacal Company, Inc. (HITK) and Impax Laboratories, Inc. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/prx-top-performer-for-thurs-par-pharmaceutical-companies/17743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HITK) Top Performer for Wed: Hi-Tech Pharmacal- Zacks #1 Rank Top Performers</title>
		<link>http://www.stockbloghub.com/2009/10/03/hitk-top-performer-for-wed-hi-tech-pharmacal-zacks-1-rank-top-performers/16354</link>
		<comments>http://www.stockbloghub.com/2009/10/03/hitk-top-performer-for-wed-hi-tech-pharmacal-zacks-1-rank-top-performers/16354#comments</comments>
		<pubDate>Sat, 03 Oct 2009 22:53:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hi Tech Pharmacal Company Inc]]></category>
		<category><![CDATA[HITK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com.php5-2.dfw1-2.websitetestlink.com/?p=16354</guid>
		<description><![CDATA[Hi-Tech Pharmacal Co., Inc. (HITK) enjoyed a strong performance from generic pharmaceuticals in its fiscal first quarter, leading to a sharp earnings surprise and large revenue growth. With a gain of only around 3.8%, HITK is a top-performing Zacks #1 Rank company today. Volume is at 514,000, versus the daily average of 586,000. HITK is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded prescription and OTC products. It specializes in difficult-to-manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The company is part of the Medical-Generic Drugs industry. There is only 1 other name from that space on today&#8217;s 218-stock Zacks #1 Rank List, and that is Impax Laboratories, Inc. (IPXL). Strong Fiscal First Quarter In early September, HITK ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/hitk-top-performer-for-wed-hi-tech-pharmacal-zacks-1-rank-top-performers/16354/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan&#8217;s Portfolio Strengthens</title>
		<link>http://www.stockbloghub.com/2009/08/28/myl-mylans-portfolio-strengthens/13810</link>
		<comments>http://www.stockbloghub.com/2009/08/28/myl-mylans-portfolio-strengthens/13810#comments</comments>
		<pubDate>Fri, 28 Aug 2009 23:56:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Incorporated]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13810</guid>
		<description><![CDATA[We are pleased to hear that Mylan (MYL) has begun to market the generic version of BenzaClin (1% Clindamycin and 5% Benzoyl Peroxide Gel) for acne treatment, which was originally manufactured by Sanofi-Aventis (SNY). The drug has been developed under an agreement between its subsidiary, Mylan Pharmaceuticals and Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. Earlier this month, Dow received the US Food and Drug Administration (FDA) approval for the generic drug. Although the approval is good news for the company, we do not expect it to contribute significantly to the top line since BenzaClin had total U.S. sales of about $221 million for the 12 months ending June 30 (as per IMS data). This is the third approval for Mylan in the month of August. A few ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/myl-mylans-portfolio-strengthens/13810/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Drug Gets Tentative OK</title>
		<link>http://www.stockbloghub.com/2009/08/19/myl-mylan-drug-gets-tentative-ok/12726</link>
		<comments>http://www.stockbloghub.com/2009/08/19/myl-mylan-drug-gets-tentative-ok/12726#comments</comments>
		<pubDate>Wed, 19 Aug 2009 21:42:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12726</guid>
		<description><![CDATA[Yesterday, Mylan Inc. (MYL) announced that its Indian subsidiary, Matrix Laboratories, received tentative approval from the US Food and Drug Administration (FDA) under the President&#8217;s Emergency Plan for AIDS Relief (PEPFAR) for its generic version of a fixed-dose combination of Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate tablets in 600 mg/200mg/300 mg dosage strengths. The decision is in response to an Abbreviated New Drug Application filed by the Indian subsidiary. The tentative approval under PEPFAR is indicative of the fact that the product satisfies all the manufacturing quality, safety and efficacy standards laid down by the agency. The Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate combination is the generic version of Gilead Sciences’ (GILD) Atripla tablets used for the treatment of HIV-1 infection in adults. It combines three anti-AIDS medicines into a single, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/myl-mylan-drug-gets-tentative-ok/12726/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

